The research aims to evaluate the therapeutic effects of Orai-1 inhibition in a Huntington disease model.
Utilized a 3-nitropropionic acid (3-NPA) model in mice to induce Huntington disease symptoms.
Administered the Orai-1 inhibitor Synta-66 to test its effects on neuroprotection.
Conducted behavioral and biochemical assessments to evaluate treatment outcomes.
Synta-66 treatment resulted in significant neuroprotective effects in the mice model.
Behavioral tests showed improved motor function in treated mice compared to non-treated groups.
Biochemical analyses indicated reduced neuronal death markers with Synta-66 administration.
Abstract
The findings suggest the therapeutic potential of targeting Orai-1 channel using the inhibitor Synta-66 could serve as a neuroprotective treatment in a 3-NPA-induced HD model in mice.